Humira
Major Health Plans Will Prefer Humira Biosimilars in 2025
The market dominance of Humira may finally be at an end, as payors make dramatic shifts in favor of biosimilars to ...
DECEMBER 12, 2024
FDA Approves Citrate-Free Formulation of Hyrimoz, a Biosimilar to Humira
The FDA approved a citrate-free high-concentration formulation of Hyrimoz injection, a biosimilar to Humira.
MARCH 31, 2023
Amjevita, First Biosimilar to Humira Launches
Adalimumab-atto, an anti-tumor necrosis factor-alpha monoclonal antibody is the first biosimilar to Humira to ...
FEBRUARY 2, 2023
FDA Approves New Formula for Hadlima, Biosimilar to Humira
The FDA approved a citrate-free, high-concentration (100 mg/mL) formulation of HADLIMA, a biosimilar referencing ...
AUGUST 23, 2022
Study Finds No Surgical Infection Risk From TNF Inhibitors
San Diego—Patients undergoing surgery with detectable levels of a tumor necrosis factor (TNF) inhibitor are ...
NOVEMBER 6, 2019
FDA Approves Adalimumab Biosimilar
The FDA has approved adalimumab-bwwd (Hadlima, Samsung Bioepis Co.), a biosimilar referencing adalimumab (Humira, ...
JULY 31, 2019
Tea Leaves No More: Biologics Head-to-Head Produces a Winner
In the first head-to-head trial of biologic treatments for inflammatory bowel disease, vedolizumab (Entyvio, ...
JUNE 11, 2019
PSP Boosts Adalimumab Adherence
Boston—A comprehensive manufacturer-sponsored patient support program (PSP) for patients prescribed ...
FEBRUARY 22, 2019
FDA Approves Cyltezo, Biosimilar of Humira
Second new adalimumab biosimilar approved for multiple indications.
AUGUST 29, 2017
